RTS names Richard Carpenter mid-Atlantic sales manager

RTS Life Science, a UK-based supplier of automated sample management and drug delivery testing systems, has appointed Richard Carpenter as mid-Atlantic sales manager.

RTS Life Science, a UK-based supplier of automated sample management and drug delivery testing systems, has appointed Richard Carpenter as mid-Atlantic sales manager. Carpenter has extensive experience in the scientific instrument market and expands the US field-based sales team.

Prior to joining RTS, Carpenter worked for LabCyte and Tecan, where he became an expert in robotics and liquid handling systems.




You may also like

Manufacturing

Software upgrade for RTS Tube Auditor

Improves screening quality, reduces costs and saves time
Regulatory

Pfizer and BioNTech’s COMIRNATY COVID-19 vaccine wins FDA approval for seniors and high-risk individuals

The COVID-19 vaccines by Pfizer and BioNTech are based on BioNTech’s proprietary mRNA technology and were developed by both companies
Manufacturing

Sovereign demonstrates turnkey bottle labelling solution at PPMA Total Show 2025

Integrated labelling and tamper-proofing technologies showcased for high-speed production lines
Manufacturing

Vapourtec unveils compact benchtop peptide synthesiser

Peptide-Builder uses VBFR technology to improve efficiency and reduce waste
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Pharma outsourcing trends 2025: partnership, precision and resilience

The Bachem team shares its insights on the evolving relationship between pharma companies and CDMOs
Manufacturing

When the chemistry is right: Vetter expands capacities with a pure water generator from Pharmatec

The production of injectable active pharmaceutical ingredients (APIs) is a highly complex process that leaves no room for error
Regulatory

Roca secures EMA recognition of radiation maculopathy as a distinct indication and Orphan Drug Designation

Roca Therapeutics (Roca) announces the granting of Orphan Drug Designation (ODD) by the European Medicines Agency (EMA) for its lead clinical candidate, RCT002, to treat radiation maculopathy
Subscribe now